Genotyping of Hepatitis C Virus (HCV) in Infected Patients from Yemen

Hassan A. Al-Shamahy 1, Sami Sultan Ahmed Abdu 2
More Detail
1 Department of Medical Microbiology, Faculty of Medicine and Health Sciences, Sana’a University
2 Al-Awalagy Medical Laboratory
EUR J BASIC MED SCI, Volume 3, Issue 4, pp. 78-82. https://doi.org/10.15197/sabad.2.3.15
OPEN ACCESS
Download Full Text (PDF)

ABSTRACT

Hepatitis C virus has been considered to be one of the most important devastating causes of chronic hepatitis, cirrhosis, and hepatic cellular carcinoma. In this area, the epidemiology of hepatitis C is not well understandable in spite it was found to be endemic in Yemen.The distribution of hepatitis C virus (HCV) genotypes in the Yemen is unknown, so a molecular study was carried to investigate the prevalence of Hepatitis C virus (HCV) genotypes in HCV infected population of Sana’a, Yemen. A total of 502 HCV-positive clinical specimens (serum, EDTA plasma) with viral loads above 2,000 IU/ml were collected for genotyping. Genotyping of 502 samples revealed four different genotypes including 1 (1a and 1b), 2a, 3 (3a) and 4. The most prevalent genotype was 4 with rate of 63.7% followed by genotype 1a+1b (26.9%), 2a (7.6%) and 3a (1.8%). Genotypes 5 and 6 were not found in our patients. The predominance of HCV genotype 4 in our population confirms the predominance of HCV genotype 4 in Yemen and similar to most of the Arab countries in the Middle East.
Keywords: genotypes, hepatitis C virus (HCV), Sana’a, Yemen

CITATION

Al-Shamahy HA, Abdu SSA. Genotyping of Hepatitis C Virus (HCV) in Infected Patients from Yemen. Eur J Basic Med Sci. 2013;3(4):78-82. https://doi.org/10.15197/sabad.2.3.15

REFERENCES

  • Lavanchy D. The global burden of hepatitis C. Liver Int 2009, 29(1):74-81.
  • Ghany MG. Diagnosis, management, and treatment of hepatitis C: An update. Hepatology 2009, 49(4): 1335-74.
  • Choo QL, Kuo G, Weiner AJ, et al. Isolation of a cDNA clone derived from a blood borne non-A, non-B hepatitis genome. Science 1989, 244(4902): 359-62.
  • Tokita H, Okamoto H, Luengrojanakul P, et al. Hepatitis C virus variants from Thailand classifiable into five novel genotypes in the sixth (6b), seventh (7c, 7d) and ninth (9b, 9c) major genetic groups. J. Gen. Virol 1995, 76(Pt 9): 2329-35.
  • Sievert W, Altraif I, Razavi HA, et al A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt. Liver International.2011; 31(supplement 2):61–80.
  • Zein NN. Clinical significance of hepatitis C virus genotypes. Clin. Microbiol Rev 2000, 13(2): 223-35.
  • John AK, Al-Kaabi S, John A, et al. Audit of state-funded antiviral treatment for chronic hepatitis C in Qatar. Eastern Mediterranean Health Journal 2010; 16(11):1121–7.
  • Hnatyszyn HJ Chronic hepatitis C and genotyping: the clinical significance of determining HCV genotypes. Antivir Ther 2005, 10(1):1-11.
  • Alter MJ. Epidemiology of hepatitis C virus infection. World Journal of Gastroenterology 2007; 13(17):2436–41.
  • Gish RG, Lua JYN. Hepatitis C virus: eight years old. Viral Hep Rev 1997, 3: 17-37.
  • Brass V, Moradpour D, Blum HE. Molecular Virology of Hepatitis C Virus (HCV). Int J Med Sci 2006, 3(2): 29-34.
  • Antaki N, Craxi A, Kamal S, et al. The neglected hepatitis C virus genotypes 4, 5 and 6: an international consensus report. Liver International 2010; 30(3):342–55.
  • Zali MR, Mayumi M, Rouf M, et al. Hepatitis C virus genotypes in the Islamic Republic of Iran: a preliminary study. Eastern Mediterr. Health J 2000, 6: 372-7.
  • Pacsa AS, Al-Mufti S, Chugh TD, Said-Adi G. Genotypes of Hepatitis C virus in Kuwait. Med. Principles Pract 2001, 10: 55-7.
  • Osaba AO. Hepatitis C virus genotypes in Saudi Arabia. Saudi Med 2002. J, 23(1): 7-12.
  • Marie Mohammed Ali M. Genotyping of Hepatitis C virus (HCV) in infected patients from Saudi Arabia. African Journal of Microbiology Research 2011, 5(16): 2388-2390.
  • Azhar EI, Jamjoom GA, Al-Ghamdi AK, et al. Hepatitis C virus infection among patients on hemodialysis in Jeddah: a single center experience. Saudi Journal of Kidney Diseases and Transplantation 2011; 14(1):84–9.
  • Sallam TA et al. Prevalence of blood-borne viral hepatitis in different community in Yemen. Epidemiology and Infection, 2003, 131(1):771–5.
  • Al-Waleedi A.A. and Y.S. Khader. Prevalence of hepatitis B and C infections and associated factors among blood donors in Aden city, Yemen. EMHJ 2012; 18(6): 1-7.
  • Haidar NA. Prevalence of hepatitis B and hepatitis C in blood donors and high risk groups in Hajjah, Yemen Republic. Saudi Medical Journal, 2002, 23(9):1090–4.
  • Selm SB. Prevalence of hepatitis C virus infection among hemodialysis patients in a single center in Yemen. Saudi J Kidney Dis Transpl 2010; 21(6):1165-8.
  • Daw M A and Dau Aghnaya A. Hepatitis C Virus in Arab World: A State of Concern. Scientific World Journal 2012; 2012:71-9.
  • McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N. Eng. J. Med 1998; 339(21): 1485-92.
  • Alfaresi MS. Prevalence of hepatitis C virus (HCV) genotypes among positive UAE patients. Molecular Biology Reports 2011; 38(4):2719–22.
  • Bdour S. Hepatitis C virus infection in Jordanian hemodialysis units, serological diagnosis and genotyping. J. Med. Microbiol 2002, 51(8):700-4.
  • Al Balwi MA. Prevalence of mixed hepatitis C virus (HCV) genotypes among recently diagnosed dialysis patients with HCV infection. Saudi Journal of Kidney Diseases and Transplantation 2011; 22(4):712–6.
  • Ray SC, Arthur RR, Carella A, et al. Genetic Epidemiology of hepatitis C throughout Egypt. J. Infect. Dis 2000, 182(3): 239-44.
  • Zekri AR, Bahnassy AA, Shaarawy SM, et al. Hepatitis C virus genotyping in relation to neu-oncoprotein over expression and the development of hepatocellular carcinoma. J. Med. Microbiol 2000, 49(1): 89-95.
  • Hadziyannis SJ, Sette HJ, Morgan TRl. Peginterferonalpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Int Med 2004; 140 (5): 346-55.